We have performed the first extensive profiling of Epstein-Barr virus (EBV) miRNAs on in vivo derived normal and neoplastic infected tissues. We describe a unique pattern of viral miRNA expression by normal infected cells in vivo expressing restricted viral latency programs (germinal center: Latency II and memory B: Latency I/0). This includes the complete absence of 15 of the 34 miRNAs profiled. These consist of 12 BART miRNAs (including approximately half of Cluster 2) and 3 of the 4 BHRF1 miRNAs. All but 2 of these absent miRNAs become expressed during EBV driven growth (Latency III). Furthermore, EBV driven growth is accompanied by a 5–10 fold down regulation in the level of the BART miRNAs expressed in germinal center and memory B cells. Therefore, Latency III also expresses a unique pattern of viral miRNAs. We refer to the miRNAs that are specifically expressed in EBV driven growth as the Latency III associated miRNAs. In EBV associated tumors that employ Latency I or II (Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma and gastric carcinoma), the Latency III associated BART but not BHRF1 miRNAs are up regulated. Thus BART miRNA expression is deregulated in the EBV associated tumors. This is the first demonstration that Latency III specific genes (the Latency III associated BARTs) can be expressed in these tumors. The EBV associated tumors demonstrate very similar patterns of miRNA expression yet were readily distinguished when the expression data were analyzed either by heat-map/clustering or principal component analysis. Systematic analysis revealed that the information distinguishing the tumor types was redundant and distributed across all the miRNAs. This resembles “secret sharing” algorithms where information can be distributed among a large number of recipients in such a way that any combination of a small number of recipients is able to understand the message. Biologically, this may be a consequence of functional redundancy between the miRNAs.
References
[1]
Rickinson AB, Kieff E (2007) Epstein-Barr Virus. In: Knipe DM, Howley PM, editors. Virology. 5th ed. New York: Lippincott Williams and Wilkins. pp. 2655–2700.
[2]
Thorley-Lawson D (2005) EBV persistence and latent infection in vivo. In: ES R, Howley PM, editors. Epstein-Barr Virus. 1st ed. Norfolk, England: Caister Academic Press. pp. 309–349.
[3]
Thorley-Lawson DA, Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 6: 913–924.
[4]
Kieff E, Rickinson AB (2007) Epstein-Barr Virus and Its Replication. In: Knipe DM, Howley PM, editors. Fields Virology 5th ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2603–2654.
[5]
Roughan JE, Thorley-Lawson DA (2009) The intersection of Epstein-Barr virus with the germinal center. J Virol 83: 3968–3976.
[6]
Roughan JE, Torgbor C, Thorley-Lawson DA (2010) Germinal center B cells latently infected with Epstein-Barr virus proliferate extensively but do not increase in number. J Virol 84: 1158–1168.
[7]
Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350: 1328–1337.
Cullen BR (2006) Viruses and microRNAs. Nat Genet 38: SupplS25–30.
[10]
Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, et al. (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2: e23.
[11]
Chen SJ, Chen GH, Chen YH, Liu CY, Chang KP, et al. (2010) Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PLoS One 5: In press.
[12]
Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, et al. (2008) On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 111: 1420–1427.
[13]
Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, et al. (2004) Identification of virus-encoded microRNAs. Science 304: 734–736.
[14]
Al-Mozaini M, Bodelon G, Karstegl CE, Jin B, Al-Ahdal M, et al. (2009) Epstein-Barr virus BART gene expression. J Gen Virol 90: 307–316.
[15]
Amoroso R, Fitzsimmons L, Thomas WA, Kelly GL, Rowe M, et al. (2011) Quantitative studies of Epstein-Barr virus-encoded microRNAs provide novel insights into their regulation. J Virol 85: 996–1010.
[16]
Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, et al. (2009) Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. J Virol 83: 2357–2367.
[17]
Imig J, Motsch N, Zhu JY, Barth S, Okoniewski M, et al. (2011) microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res 39: 1880–1893.
[18]
Pratt ZL, Kuzembayeva M, Sengupta S, Sugden B (2009) The microRNAs of Epstein-Barr Virus are expressed at dramatically differing levels among cell lines. Virology 386: 387–397.
[19]
Gibcus JH, Tan LP, Harms G, Schakel RN, de Jong D, et al. (2009) Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia 11: 167–176.
[20]
Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, et al. (2009) Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 13: 1248–1260.
[21]
Liang Y, Ridzon D, Wong L, Chen C (2007) Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8: 166.
[22]
Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, et al. (2009) Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 113: 3754–3764.
[23]
Van Vlierberghe P, De Weer A, Mestdagh P, Feys T, De Preter K, et al. (2009) Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol 147: 686–690.
[24]
Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, et al. (2009) Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 113: 4586–4594.
[25]
Feederle R, Linnstaedt SD, Bannert H, Lips H, Bencun M, et al. (2011) A Viral microRNA Cluster Strongly Potentiates the Transforming Properties of a Human Herpesvirus. PLoS Pathog 7: In press.
[26]
Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, et al. (2010) Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog 6: e1001063.
[27]
Xing L, Kieff E (2007) Epstein-Barr Virus BHRF1 Micro- and Stable RNAs during Latency III and after Induction of Replication. J Virol 81: 9967–9975.
[28]
Xia T, O'Hara A, Araujo I, Barreto J, Carvalho E, et al. (2008) EBV microRNAs in primary lymphomas and targeting of CXCL-11 by ebv-mir-BHRF1-3. Cancer Res 68: 1436–1442.
[29]
Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, et al. (2008) Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res 36: 666–675.
[30]
Lo AK, To KF, Lo KW, Lung RW, Hui JW, et al. (2007) Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci U S A 104: 16164–16169.
[31]
Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, et al. (2009) Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 11: 1174–1184.
[32]
Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, et al. (2008) An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 205: 2551–2560.
[33]
Marquitz AR, Mathur A, Nam CS, Raab-Traub N (2011) The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 412: 392–400.
[34]
Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O (2009) Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 5: 376–385.
[35]
Robertson ES, Tomkinson B, Kieff E (1994) An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol 68: 1449–1458.
[36]
Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405–411.
[37]
Longnecker R, Miller CL, Miao XQ, Tomkinson B, Kieff E (1993) The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro. J Virol 67: 2006–2013.
Shamir A (1979) How to share a secret. Commun ACM 22: 612–613.
[40]
Laichalk LL, Hochberg D, Babcock GJ, Freeman RB, Thorley-Lawson DA (2002) The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 16: 745–754.
[41]
Marquitz AR, Mathur A, Nam CS, Raab-Traub N (2011) The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 412: 392–400.
[42]
Edwards RH, Marquitz AR, Raab-Traub N (2008) Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 82: 9094–9106.
[43]
Cheung HH, Davis AJ, Lee TL, Pang AL, Nagrani S, et al. (2011) Methylation of an intronic region regulates miR-199a in testicular tumor malignancy. Oncogene. In press.
[44]
Datta J, Kutay H, Nasser MW, Nuovo GJ, Wang B, et al. (2008) Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049–5058.
[45]
Han L, Witmer PD, Casey E, Valle D, Sukumar S (2007) DNA methylation regulates MicroRNA expression. Cancer Biol Ther 6: 1284–1288.
[46]
Iizasa H, Wulff BE, Alla NR, Maragkakis M, Megraw M, et al. (2010) Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem 285: 33358–33370.
[47]
Kim DN, Song YJ, Lee SK (2011) The Role of Promoter Methylation in Epstein-Barr Virus MicroRNA Expression in EBV-infected B cell lines. Exp Mol Med. In press.
[48]
Chatterjee S, Fasler M, Bussing I, Grosshans H (2011) Target-mediated protection of endogenous microRNAs in C. elegans. Dev Cell 20: 388–396.
[49]
Abbott AL, Alvarez-Saavedra E, Miska EA, Lau NC, Bartel DP, et al. (2005) The let-7 MicroRNA family members mir-48, mir-84, and mir-241 function together to regulate developmental timing in Caenorhabditis elegans. Dev Cell 9: 403–414.
[50]
Allen RS, Li J, Stahle MI, Dubroue A, Gubler F, et al. (2007) Genetic analysis reveals functional redundancy and the major target genes of the Arabidopsis miR159 family. Proc Natl Acad Sci U S A 104: 16371–16376.
[51]
Iwama H, Murao K, Imachi H, Ishida T (2011) MicroRNA networks alter to conform to transcription factor networks adding redundancy and reducing the repertoire of target genes for coordinated regulation. Mol Biol Evol 28: 639–646.
[52]
Sieber P, Wellmer F, Gheyselinck J, Riechmann JL, Meyerowitz EM (2007) Redundancy and specialization among plant microRNAs: role of the MIR164 family in developmental robustness. Development 134: 1051–1060.
[53]
Kim do N, Chae HS, Oh ST, Kang JH, Park CH, et al. (2007) Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 81: 1033–1036.
[54]
Chen MR, Middeldorp JM, Hayward SD (1993) Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol 67: 4875–4885.
[55]
Meij P, Vervoort MB, Meijer CJ, Bloemena E, Middeldorp JM (2000) Production monitoring and purification of EBV encoded latent membrane protein 1 expressed and secreted by recombinant baculovirus infected insect cells. J Virol Methods 90: 193–204.
[56]
Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA (2007) Influence of EBV on the peripheral blood memory B cell compartment. J Immunol 179: 3153–3160.
[57]
Hutzinger R, Feederle R, Mrazek J, Schiefermeier N, Balwierz PJ, et al. (2009) Expression and processing of a small nucleolar RNA from the Epstein-Barr virus genome. PLoS Pathog 5: e1000547.
